08:30 AM

Bayer to present new data from the company’s growing radiology portfolio

Not intended for U.S. and UK - Media 2022 European Congress of Radiology:

Featured presentations include development compound gadoquatrane, a novel contrast agent for MRI / Further data to highlight research efforts to drive innovation in AI

Abstracts: RPS 2311-2, RPS 2311-7, RPS 1105-11, RPS 811-4

Berlin, July 11, 2022 – Bayer announced today that new data from the company’s growing radiology portfolio will be presented at the 2022 European Congress of Radiology (ECR), taking place from July 13 to 17 in Vienna, Austria. The presentations reinforce Bayer’s position as a leading company in key radiology areas and its commitment to accelerate innovation for the ultimate benefit of patients and their physicians, including leveraging the vast potential of artificial intelligence (AI).

The presentations highlight preclinical data on the novel development compound gadoquatrane, which is currently in Phase II development. Gadoquatrane features high stability as well as high relaxivity, which is a key property for use in contrast-enhanced magnetic resonance imaging (MRI), with the potential to enable a substantially lower gadolinium (Gd) dose. Another focus is on clinical data on Bayer’s MRI contrast agent Gadovist™ (gadobutrol), investigating the clinical efficacy of a reduced dose of gadobutrol compared to a standard dose of gadoterate in patients undergoing a steady-state contrast-enhanced MRI of the central nervous system (CNS).

Artificial intelligence is currently one of the most-discussed topics in radiology and will be one of the highlights of the ECR again this year. Bayer is committed to further driving advances in AI. At this year’s ECR, one early research presentation by Bayer explores the potential of deep learning to achieve optimized contrast media administration utilizing a generative adversarial network. AI can help manage the mounting workload of radiologists and their teams, ultimately striving to improve patient care. Bayer recently announced the launch of Calantic Digital Solutions, a new platform delivering access to digital applications, including artificial intelligence enabled programs, for medical imaging. The offering contains tools which aid radiologists and their teams to improve prioritization, lesion detection, quantification and productivity.

By providing access to AI radiology applications through the Calantic Digital Solutions platform Bayer will expand its comprehensive portfolio beyond contrast media, medical devices, software and services. The new platform will support healthcare professionals at all stages of their work from diagnosis through treatment of their patients. First launch markets will include the US and several European countries, with more regions to follow, each upon local regulatory approvals as applicable.

Notable data to be presented by Bayer at the meeting and additional information about the topics are listed below. More details on the congress program can be found here.


·      Gadoquatrane – a new tetrameric, high relaxivity, macrocyclic gadolinium-based contrast agent for MRI

o   The novel tetrameric Gd-chelate in Phase II combines high stability and high relaxivity. The high relaxivity could offer the opportunity to use a substantially lower Gd dose.

o   Part of the overall research presentation session “Contrast agents meet neuroimaging”

o   Abstract RPS 2311-2; July 17, 09:30 – 10:30 CEST


·       Clinical efficacy of reduced-dose gadobutrol vs standard-dose gadoterate in contrast-enhanced CNS imaging: an international, multicentre, prospective, cross-over trial (LEADER-75)

o   The Phase IV, multicenter, controlled, cross-over study LEADER-75 with corresponding blinded image evaluations met its primary endpoint, showing that a 75 percent dose of gadobutrol (0.075 mmol/kg) is non-inferior to a 100 percent dose of gadoterate (0.1 mmol/kg) for CNS imaging.

o   The mean scores for the combined images differed by less than 1 percent. A post-hoc analysis for equivalence of reduced-dose gadobutrol and standard-dose gadoterate was performed using two one-sided tests with a 5 percent margin and supported equivalence for all three variables (p≤0.025). Number of lesions detected, diagnostic accuracy and image quality were similar.

o   Part of the overall research presentation session “Contrast agents meet neuroimaging”

o   Abstract RPS 2311-7; July 17, 09:30 – 10:30 CEST

Artificial Intelligence

·       Contrast media reduction in CT with deep learning utilising a generative adversarial network in an experimental animal study

o   The early research study explored the potential reduction of an iodine-containing contrast medium dose in abdominal CT by virtual contrast enhancement using generative adversarial networks (GAN).

o   This feasibility study indicates a potential promise that the amount of contrast media for abdominal CT might be reduced by about 71.4 percent using GAN-based contrast enhancement while maintaining comparable image quality.

o   Part of the overall research presentation session “Radiology workflow evolution and new developments”

o   Abstract RPS 1105-11; July 14, 16:00 – 17:30 CEST

Further Research

·       Gadolinium presence in the skin: assessment of intraepidermal nerve fiber density in rat foot skin samples after multiple administrations of gadolinium-based contrast agents

o   Gadolinium (Gd) presence in the body after multiple exposures to GBCAs has been part of intensive research in recent years. The current animal study investigated marketed extracellular GBCAs and evaluated the skin of rat foot pads for Gd presence and neuro-histological changes after repeated administration of GBCAs.

o   Using a multiple dosing regimen and an examination 5 weeks after last GBCA administration, there were no signs of small fiber neuropathy in the skin of the foot pads.

o   Part of the overall research presentation session “New techniques in neuro imaging”

o   Abstract RPS 811-4; July 14, 10:30 – 12:00 CEST

About Radiology at Bayer

Everyone deserves clear answers about their health, starting with an early and accurate diagnosis. As a true life science company with a heritage of over 100 years in radiology, Bayer is committed to providing excellence, from innovative products to high-quality services. Bayer has a leading portfolio of contrast media for computed tomography (CT), X-ray, and magnetic resonance imaging (MRI), devices for their precise administration, informatics solutions to support efficient and optimized patient care, as well as acknowledged educational programs, that generated sales of 1.8 billion euros in 2021. In line with the company’s ambition to outperform the radiology market’s average annual growth of 5 percent by 2030, Bayer is strongly committed to research and development, which includes leveraging artificial intelligence and driving innovation in medical imaging. Each of these offerings provides effective tools to support radiologists in their mission to deliver treatment-critical answers and a clear direction – from diagnosis to care.


About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.

Find more information at https://pharma.bayer.com/

Follow us on Facebook: http://www.facebook.com/bayer

Follow us on Twitter: @BayerPharma


Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.



Sign up for our Newsletter

We will keep you informed about the latest news.